Left ventricular assist device
A left ventricular assist device (LVAD) is a pump that helps the left ventricle move blood. MeSH describes heart-assist pumps as small, often implantable, with a pumping chamber and a power source that may sit partly or fully outside the body. In the United States the HeartMate 3 system holds premarket approval P160054. Its approval orders state an indication for short-term support (2017) and later for short- and long-term support, including destination therapy (2018), in advanced refractory left ventricular heart failure.
Also called LVAD · Left ventricular assist system
- Technology
- In this atlas
Overview
Technical summary
MeSH descriptor D006353 (Heart-Assist Devices) is a broad match: its scope note says the pumps are for temporarily assisting the heart, which is narrower than durable LVAD support in time, and wider in device type. FDA product code DSQ (Ventricular (Assist) Bypass), class 3, is a broad match: its name does not limit it to the left ventricle or to one system, and the openFDA classification record is read only for its name and class. The approval facts are for one device family, HeartMate 3 (premarket approval P160054; original order 2017-08-23, supplement S008 2018-10-18). The registry entry for MOMENTUM 3 is filed on the implantation page.
How it works
A left ventricular assist device is a pump that helps the left ventricle move blood. MeSH describes heart-assist pumps as having a pumping chamber and a power source, which may be partly or fully outside the body.
Classification codes
-
D006353 -
DSQVentricular (Assist) Bypass
Limitations
- The sources read here are two FDA approval orders and a registry entry; they state indications and a study design, and no result is recorded on this page.
- The approval facts cover one device family only.
Required infrastructure
- The MeSH scope note says the power source may be partially or totally external to the body.
Claims and evidence
Context Patients for whom the US approval orders of the HeartMate 3 Left Ventricular Assist System state an indication: advanced refractory left ventricular heart failure
- Recipient
- Recipient not specified
- Population
- Patients with advanced refractory left ventricular heart failure, as the approval order statements describe them. The statements read here do not name an age group.
- Care setting
- Implanted left ventricular assist system
- Geography
- United States (premarket approval of the US Food and Drug Administration)
- Life stage
- Not stated in the statements read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with advanced refractory left ventricular heart failure
- Excluded
- None stated
The openFDA record of premarket approval P160054 (Abbott Medical) lists approval of the HeartMate 3 Left Ventricular Assist System on 23 August 2017 under product code DSQ. The approval order states the indication as short-term hemodynamic support, such as bridge to transplant or bridge to myocardial recovery, in patients with advanced refractory left ventricular heart failure. Supplement S008, approved on 18 October 2018, states the indication as short- and long-term mechanical circulatory support, such as bridge to transplant or myocardial recovery, or destination therapy, in the same patients.
Applies to Recipient not specified Patients for whom the US approval orders of the HeartMate 3 Left Ventricular Assist System state an indication: advanced refractory left ventricular heart failure
- Certainty method
- Not assessed
- Limitations
- This claim covers one device family, the HeartMate 3 system approved under P160054 (product code DSQ). It does not cover other implantable pumps. Only two of the 133 openFDA records for P160054 are read, and later supplements may change the wording. A search listing also showed a 2020 labeling update on pediatric uses and a 2022 update to the instructions for use; neither was read. An FDA approval is a decision about a device, not a finding about how well it works. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (12)
-
- Locator
- results[0].pma_number
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].applicant
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].trade_name
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].decision_date
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].decision_code
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].product_code
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].ao_statement, fragment 1 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].ao_statement, fragment 2 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2017-08-23
- Source state
- Current
- Version fingerprint
51f42e65de3cb94f8b7cbf4ae55486fe4f6ef3315b1d79a24a21ac26344f0a60- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].supplement_number
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2018-10-18
- Source state
- Current
- Version fingerprint
76e473079df9a05275390fde81870ba2bce782dddc37138185651f8ca6c1792b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].decision_date
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2018-10-18
- Source state
- Current
- Version fingerprint
76e473079df9a05275390fde81870ba2bce782dddc37138185651f8ca6c1792b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].ao_statement, fragment 1 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2018-10-18
- Source state
- Current
- Version fingerprint
76e473079df9a05275390fde81870ba2bce782dddc37138185651f8ca6c1792b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].ao_statement, fragment 2 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2018-10-18
- Source state
- Current
- Version fingerprint
76e473079df9a05275390fde81870ba2bce782dddc37138185651f8ca6c1792b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). The raw records are committed in the atlas repository. They include contact, address and registration fields that FDA publishes; records here do not repeat them.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact US approval orders for HeartMate 3 state support in advanced refractory left ventricular heart failure: Heart failure
Applies to Recipient not specified Patients for whom the US approval orders of the HeartMate 3 Left Ventricular Assist System state an indication: advanced refractory left ventricular heart failure
The openFDA record of premarket approval P160054 (Abbott Medical) lists approval of the HeartMate 3 Left Ventricular Assist System on 23 August 2017 under product code DSQ. The approval order states the indication as short-term hemodynamic support, such as bridge to transplant or bridge to myocardial recovery, in patients with advanced refractory left ventricular heart failure. Supplement S008, approved on 18 October 2018, states the indication as short- and long-term mechanical circulatory support, such as bridge to transplant or myocardial recovery, or destination therapy, in the same patients.Limitations. This claim covers one device family, the HeartMate 3 system approved under P160054 (product code DSQ). It does not cover other implantable pumps. Only two of the 133 openFDA records for P160054 are read, and later supplements may change the wording. A search listing also showed a 2020 labeling update on pediatric uses and a 2022 update to the instructions for use; neither was read. An FDA approval is a decision about a device, not a finding about how well it works. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
Record details
- Record id
cardio:left-ventricular-assist-device- Content hash
05cb18dd5f8a5e0541641e133f1972530d26032820610acb8d0470d6c9eb06e8